Clinical trials: B-Cell Lymphoblastic Leukemia
- Condition B-Cell Lymphoblastic Leukemia
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Lymphocytic Leukemia, Chronic
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)
This open-label, randomized, 3-arm study will evaluate the efficacy and safety of (obinutuzumab) RO5072759 in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with…
- Trial name
- NCT02053610
- Testing
- obinutuzumab, rituximab, chlorambucil
- Where
- 261 sites in United States, Argentina and 24 more
- Volunteers
- 787 people
- Sponsor
- Hoffmann-La Roche
Leukaemia
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
The purpose of this study was to confirm the clinical benefit observed in the pivotal registration study, Hx-CD20-406. The Committee for Medicinal Products for Human Use (CHMP) required that a randomized study be conducted in CLL…
- Trial name
- NCT01313689
- Testing
- Ofatumumab, Physicians' Choice
- Where
- 80 sites in Austria, Belgium and 15 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Lymphocytic Leukemia, Chronic
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
This randomized, open-label, parallel group study will assess the effect on response rate and the safety of MabThera added to either bendamustine or chlorambucil in patients with chronic lymphocytic leukemia.
- Trial name
- NCT01056510
- Testing
- bendamustine, chlorambucil, rituximab [MabThera/Rituxan]
- Where
- 85 sites in Finland, France and 6 more
- Volunteers
- 357 people
- Sponsor
- Hoffmann-La Roche
Leukaemia, Lymphocytic, Chronic
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
The purpose of this study is to determine whether HuMax-CD20 (ofatumumab) is effective in the treatment of patients failing both fludarabine and alemtuzumab.
- Trial name
- NCT00349349
- Testing
- ofatumumab
- Volunteers
- 223 people
- Sponsor
- GlaxoSmithKline
Chronic Lymphocytic Leukemia
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
The primary objective of this study is to evaluate the effect of the addition of idelalisib to ofatumumab on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL).
- Trial name
- NCT01659021
- Testing
- Idelalisib, Ofatumumab
- Where
- 80 sites in United States, Australia and 9 more
- Volunteers
- 261 people
- Sponsor
- Gilead Sciences
Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
The purpose of the study is to evaluate whether treatment with ibrutinib as a monotherapy results in a clinically significant improvement in progression free survival (PFS) as compared to treatment with ofatumumab in patients…
- Trial name
- RESONATE™ (NCT01578707)
- Testing
- ofatumumab, ibrutinib
- Where
- 76 sites in United States, Australia and 8 more
- Volunteers
- 391 people
- Sponsor
- Pharmacyclics LLC.
Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma
This is a Phase 1 dose-exploration study of LAM-002A administered by mouth in patients with relapsed or refractory B-cell NHL. Safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD),and preliminary anti-tumor activity…
- Trial name
- LAM-002A/NHL (NCT02594384)
- Testing
- LAM-002A, Rituximab, Atezolizumab
- Where
- 11 sites in United States
- Volunteers
- 62 people
- Sponsor
- IRulya Therapeutics Inc.
Leukemia, Lymphocytic, Chronic, B-Cell
Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
The trial is a Phase II, open label, Simon's two stage study design to evaluate the efficacy and safety of Tenalisib in patients with CLL who have relapsed or are refractory after at least one prior therapy.
- Trial name
- NCT04204057
- Testing
- Tenalisib
- Where
- 6 sites in Bulgaria, Georgia and 1 more
- Volunteers
- 21 people
- Sponsor
- Rhizen Pharmaceuticals SA
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely combined at the recommended Phase 2 dose (RP2D) and dosing regimen that was…
- Trial name
- topMIND (NCT04809467)
- Testing
- tafasitamab, parsaclisib
- Where
- 50 sites in United States, Austria and 5 more
- Volunteers
- 54 people
- Sponsor
- Incyte Corporation
Chronic Lymphocytic Leukemia
A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to evaluate the efficacy of venetoclax monotherapy in participants with relapsed/refractory CLL with or without the 17p deletion or TP53 mutation, including those who have received prior treatment…
- Trial name
- VENICE I (NCT02756611)
- Testing
- Venetoclax
- Where
- 67 sites in United States, Austria and 19 more
- Volunteers
- 258 people
- Sponsor
- AbbVie
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
The purpose of this study is to determine the long-term safety of a fixed-dose, daily regimen of PCI-32765 PO in subjects with B cell lymphoma or chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Well-differentiated Lymphocytic Lymphoma, B Cell Lymphoma
- Trial name
- NCT01109069
- Testing
- PCI-32765
- Where
- 16 sites in United States
- Volunteers
- 199 people
- Sponsor
- Pharmacyclics LLC.
Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
This multi-center, open-label, single-arm study will evaluate the pharmacokinetics and safety of obinutuzumab in participants with cluster of differentiation (CD) 20 positive (+) malignant disease.
- Trial name
- NCT01680991
- Testing
- Obinutuzumab
- Where
- 4 sites in China
- Volunteers
- 48 people
- Sponsor
- Hoffmann-La Roche
Lymphocytic Leukemia, Chronic
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
This study will assess the effect of maintenance treatment with rituximab in comparison with observation period (no treatment), in participants with progressive B-cell CLL who have had previous first-line induction treatment with…
- Trial name
- NCT00718549
- Testing
- Cladribine, Cyclophosphamide, Rituximab
- Where
- 6 sites in Belarus, Poland
- Volunteers
- 128 people
- Sponsor
- Hoffmann-La Roche
Leukaemia, Lymphocytic, Chronic
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
This is an open-label study to evaluate tolerability, safety, efficacy and pharmacokinetic profile of ofatumumab in combination with chlorambucil in Japanese patients with previously untreated Chronic Lymphocytic Leukemia (CLL).
- Trial name
- NCT01563055
- Testing
- chlorambucil, tablets, ofatumumab (GSK1841157) infusion
- Where
- 6 sites in Japan
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Post Acute Coronary Syndrome, Myocardial Ischemia
Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome
The purpose of this study is to test the hypothesis that the inhibition of the renin-angiotensin-aldosterone system (RAAS) with the angiotensin receptor blocker valsartan or the renin antagonist aliskiren will improve ventricular…
- Trial name
- NCT00409578
- Testing
- Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 1,101 people
- Sponsor
- Novartis
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
Study to determine the preliminary safety, tolerability, and pharmacokinetic (PK) profile of APR-246 in combination with either acalabrutinib or venetoclax + rituximab therapy in subjects with NHL, including relapsed and/or…
- Conditions
- Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
- Trial name
- R/R (NCT04419389)
- Testing
- APR-246 (eprenetapopt) + Acalabrutinib in CLL, APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL, APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Aprea Therapeutics
Chronic Lymphocytic Leukemia
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
The main objective of this study is to determine the progression free survival of umbralisib in participants who were intolerant to prior BTK (Bruton Tyrosine Kinase) inhibitors (ibrutinib, ACP-196, other) or prior PI3K-delta…
- Trial name
- NCT02742090
- Testing
- Umbralisib
- Where
- 15 sites in United States
- Volunteers
- 51 people
- Sponsor
- TG Therapeutics, Inc.
Leukemia, Lymphocytic, Chronic, B-Cell
BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)
Adult patients with chronic lymphocytic leukaemia who experience a relapse after at least two prior treatment regimens may be enrolled in this trial.
- Trial name
- NCT01296932
- Testing
- BI 836826
- Where
- 10 sites in Belgium, France and 1 more
- Volunteers
- 37 people
- Sponsor
- Boehringer Ingelheim
Lymphocytic Leukemia, Chronic
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
This single arm, open-label study will assess the safety and efficacy of low dose fludarabine and cyclophosphamide in combination with standard dose MabThera/Rituxan (rituximab) as primary therapy in elderly patients (>/= 65…
- Trial name
- NCT01263704
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 12 sites in Israel
- Volunteers
- 42 people
- Sponsor
- Hoffmann-La Roche